Unicycive presents new patient-level data from Phase 2 study of OLC

Unicycive Therapeutics (UNCY) announced new patient-reported outcomes data from its pivotal Phase 2 study of OLC as well as from a new survey conducted by the National Kidney Foundation with sponsorship from Unicycive. OLC is an investigational treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis. The findings will be presented today in poster sessions at the NKF Spring Clinical Meetings taking place in Boston. OLC leverages proprietary nanoparticle technology to reduce the number and size of pills that patients must take. The U.S. Food and Drug Administration accepted the New Drug Application for OLC for the treatment of hyperphosphatemia in patients with CKD on dialysis and set a Prescription Drug User Fee Act Target Action Date of June 28, 2025. Patient-Reported Outcomes Data, Results: OLC reduced pill burden by 50% – patients took a median of three tablets of OLC per day versus six tablets of phosphate binders prior to the trial. OLC improved adherence – 70% of patients reported consistent adherence with OLC compared to 58% who reported adherence to their pre-trial phosphate binders. OLC was preferred – 79% of patients indicated a preference for OLC versus 4% who preferred their pre-trial phosphate binder medications. OLC improved patient satisfaction – 98% of patients agreed that OLC was easy to take versus 38% who said that about their pre-trial phosphate binder medication, and 89% reported they were satisfied with OLC treatment versus 49% who were satisfied with pre-trial phosphate binders.